Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Mochida Seeks Japan Approval of Once-Daily Epadel
June 23, 2021
- Nichi-Iko Halts Supplies of Some Edirol Generic Products, Re-Supply Expected for September
June 22, 2021
- Yoshindo Announces Shipment Curbs for Cymbalta Generics, 6 Other APIs
June 22, 2021
- Otsuka Group Takes the Lead to Launch Workplace Vaccination as Industry Peers Set to Follow
June 22, 2021
- NanoCarrier’s Angiosarcoma Med Bags US FDA’s Fast Track Designation
June 22, 2021
- Yoshindo’s Cymbalta Generics Out, but Supply Restrictions in Place: Sources
June 21, 2021
- Astellas CEO Earns 488 Million Yen in FY2020: Securities Filing
June 21, 2021
- Global Brands Clinch Targeted Sales despite COVID-19, Drive Japan Makers in FY2020
June 21, 2021
- Eisai Forms Strategic Alliance with BMS for Its First ADC
June 21, 2021
- Astellas to Write Off 21.5 Billion Yen as Peanut Allergy Vaccine Fails
June 18, 2021
- Merck’s COVID-19 Drug Candidate Enters PIII in Japan
June 18, 2021
- Zacras AG Now Available, Aloxi AG Expected for September Launch
June 18, 2021
- Kyowa Adjusting Cymbalta Generic Supply before Launch as Rivals Delay Release
June 18, 2021
- Nichi-Iko Licenses Its Remicade Biosimilar to Argentine Drug Maker
June 18, 2021
- Delays in Cymbalta Generic Launch Stir Worries on Demand Spike for 2 Makers
June 17, 2021
- Astellas Offloads 5 Legacy Products to Germany’s Cheplapharm
June 17, 2021
- Daiichi Sankyo Ships AstraZeneca COVID-19 Vaccine to Taiwan, Vietnam
June 17, 2021
- Kitasato Institute, Meiji Eye Ivermectin Derivative Use for Post-COVID-19 Symptoms Too
June 16, 2021
- Enhertu Enters PIII for 1st Line HER2-Positive Breast Cancer
June 16, 2021
- Daiichi Sankyo Drops Nafamostat Development for COVID-19
June 16, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…